329 related articles for article (PubMed ID: 27821803)
1. Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy.
Ahn HM; Hong J; Yun CO
Oncotarget; 2016 Dec; 7(51):84965-84980. PubMed ID: 27821803
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model.
Oh E; Choi IK; Hong J; Yun CO
Oncotarget; 2017 Jan; 8(3):4730-4746. PubMed ID: 28002796
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.
Lee YS; Kim JH; Choi KJ; Choi IK; Kim H; Cho S; Cho BC; Yun CO
Clin Cancer Res; 2006 Oct; 12(19):5859-68. PubMed ID: 17020994
[TBL] [Abstract][Full Text] [Related]
4. Strengthening of antitumor immune memory and prevention of thymic atrophy mediated by adenovirus expressing IL-12 and GM-CSF.
Choi KJ; Zhang SN; Choi IK; Kim JS; Yun CO
Gene Ther; 2012 Jul; 19(7):711-23. PubMed ID: 21993173
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα.
Choi IK; Lee JS; Zhang SN; Park J; Sonn CH; Lee KM; Yun CO
Gene Ther; 2011 Sep; 18(9):898-909. PubMed ID: 21451575
[TBL] [Abstract][Full Text] [Related]
6. VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth.
Yoo JY; Kim JH; Kwon YG; Kim EC; Kim NK; Choi HJ; Yun CO
Mol Ther; 2007 Feb; 15(2):295-302. PubMed ID: 17235307
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic adenovirus expressing IL-23 and p35 elicits IFN-γ- and TNF-α-co-producing T cell-mediated antitumor immunity.
Choi IK; Li Y; Oh E; Kim J; Yun CO
PLoS One; 2013; 8(7):e67512. PubMed ID: 23844018
[TBL] [Abstract][Full Text] [Related]
8. Optimized biodegradable polymeric reservoir-mediated local and sustained co-delivery of dendritic cells and oncolytic adenovirus co-expressing IL-12 and GM-CSF for cancer immunotherapy.
Oh E; Oh JE; Hong J; Chung Y; Lee Y; Park KD; Kim S; Yun CO
J Control Release; 2017 Aug; 259():115-127. PubMed ID: 28336378
[TBL] [Abstract][Full Text] [Related]
9. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
[TBL] [Abstract][Full Text] [Related]
10. Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF.
Zhang SN; Choi IK; Huang JH; Yoo JY; Choi KJ; Yun CO
Mol Ther; 2011 Aug; 19(8):1558-68. PubMed ID: 21468000
[TBL] [Abstract][Full Text] [Related]
11. Potent and long-term antiangiogenic efficacy mediated by FP3-expressing oncolytic adenovirus.
Choi IK; Shin H; Oh E; Yoo JY; Hwang JK; Shin K; Yu DC; Yun CO
Int J Cancer; 2015 Nov; 137(9):2253-69. PubMed ID: 25944623
[TBL] [Abstract][Full Text] [Related]
12. Dual tumor targeting with pH-sensitive and bioreducible polymer-complexed oncolytic adenovirus.
Moon CY; Choi JW; Kasala D; Jung SJ; Kim SW; Yun CO
Biomaterials; 2015 Feb; 41():53-68. PubMed ID: 25522965
[TBL] [Abstract][Full Text] [Related]
13. Intratumor injection of oncolytic adenovirus expressing HSP70 prolonged survival in melanoma B16 bearing mice by enhanced immune response.
Ren Z; Ye X; Fang C; Lu Q; Zhao Y; Liu F; Liang M; Hu F; Chen HZ
Cancer Biol Ther; 2008 Feb; 7(2):191-95. PubMed ID: 18073525
[TBL] [Abstract][Full Text] [Related]
14. Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity.
Lapteva N; Aldrich M; Weksberg D; Rollins L; Goltsova T; Chen SY; Huang XF
J Immunother; 2009; 32(2):145-56. PubMed ID: 19238013
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antitumor immune response mediated by paclitaxel-conjugated nanohybrid oncolytic adenovirus with dendritic cell therapy.
Kim IW; Yoon AR; Hong J; Kasala D; Yun CO
Front Immunol; 2024; 15():1355566. PubMed ID: 38835775
[TBL] [Abstract][Full Text] [Related]
16. Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses.
Furumoto K; Arii S; Yamasaki S; Mizumoto M; Mori A; Inoue N; Isobe N; Imamura M
Int J Cancer; 2000 Sep; 87(5):665-72. PubMed ID: 10925360
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment.
Hewitt SL; Bailey D; Zielinski J; Apte A; Musenge F; Karp R; Burke S; Garcon F; Mishra A; Gurumurthy S; Watkins A; Arnold K; Moynihan J; Clancy-Thompson E; Mulgrew K; Adjei G; Deschler K; Potz D; Moody G; Leinster DA; Novick S; Sulikowski M; Bagnall C; Martin P; Lapointe JM; Si H; Morehouse C; Sedic M; Wilkinson RW; Herbst R; Frederick JP; Luheshi N
Clin Cancer Res; 2020 Dec; 26(23):6284-6298. PubMed ID: 32817076
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL.
Huang JH; Zhang SN; Choi KJ; Choi IK; Kim JH; Lee MG; Lee M; Kim H; Yun CO
Mol Ther; 2010 Feb; 18(2):264-74. PubMed ID: 19738604
[TBL] [Abstract][Full Text] [Related]
19. pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis.
Choi JW; Jung SJ; Kasala D; Hwang JK; Hu J; Bae YH; Yun CO
J Control Release; 2015 May; 205():134-43. PubMed ID: 25575865
[TBL] [Abstract][Full Text] [Related]
20. Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor model.
Yang Z; Zhang Q; Xu K; Shan J; Shen J; Liu L; Xu Y; Xia F; Bie P; Zhang X; Cui Y; Bian XW; Qian C
PLoS One; 2012; 7(9):e44802. PubMed ID: 23028626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
